Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

This Dangerous Fungus Has Become Resistant to Every Major Antifungal Drug We Have... Twice : ScienceAlert (opens in a new tab)

This Dangerous Fungus Has Become Resistant to Every Major Antifungal Drug We Have... Twice · 2026-10-03

Short answerEvidenceSource

Short answer

Needs review

Study found.

We found the study, but the claim check did not finish.

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1

The story

This Dangerous Fungus Has Become Resistant to Every Major Antifungal Drug We Have... Twice : ScienceAlert

This Dangerous Fungus Has Become Resistant to Every Major Antifungal Drug We Have... Twice · 2026-10-03

The story’s checkable claims.

Read the original story (opens in a new tab)
2

NewsLink checks it

We found the study behind this story.

We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.

Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.

Claim 1 of 5Not checkedA new paper describes a Candida auris strain that was resistant to all four major classes of antifungal drugs.View evidenceHide evidence

As statedall four major classes

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 2 of 5Not checkedThe isolate came from a 28-year-old woman who developed a hospital-acquired surgical-site infection after elective surgery in Nairobi, Kenya, and the article says this is the first such case in Africa.View evidenceHide evidence

As statedfirst such case in Africa

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 3 of 5Not checkedThe article says the strain was pan-drug-resistant, meaning it resisted drugs such as fluconazole, caspofungin, micafungin, amphotericin B, and flucytosine, and that it was the first PDR C. auris identified in Africa and only the second globally documented case.View evidenceHide evidence

As statedfirst in Africa; second globally documented case

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 4 of 5Not checkedWhole-genome sequencing found mutations previously associated with antifungal resistance, including changes in ERG11, CDR1, FKS1, and a stop-gain mutation in FUR1.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Claim 5 of 5Not checkedThe researchers suggest the mutations differ from those in a previously reported New York strain, raising the possibility that pan-drug resistance evolved independently in Kenya, although they could not rule out importation or determine whether prior antifungal exposure selected for resistance in this patient.View evidenceHide evidence

Not checked

The source study was found, but this claim couldn't be checked against it.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

Emergence of pan-drug resistant Candidozyma auris in Kenya, the second globally documented case

Scientific Reports · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, PubMed, Europe PMC · 16 candidate papers

Selected

Emergence of pan-drug resistant Candidozyma auris in Kenya, the second globally documented case

Scientific Reports · 2026 · Crossref

Source (opens in a new tab)

And 10 more candidates considered.